Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
The Journal of Antimicrobial Chemotherapy|November 17, 2015
Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial)Lionel Piroth, Laetitia Moinot, Patrick Yeni, et al.
AIDS (London, England)|December 20, 2003
An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistanceBrian G Gazzard, Anton L Pozniak, Willy Rosenbaum, et al.
Antimicrobial Agents and Chemotherapy|February 2, 2011
Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavirLucile Larrouy, Sidonie Lambert-Niclot, Charlotte Charpentier, et al.
The Journal of Antimicrobial Chemotherapy|November 27, 2018
Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)Véronique Joly, Charles Burdet, Roland Landman, et al.
Lancet (London, England)|August 8, 2006
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialJoseph Eron, Patrick Yeni, Joseph Gathe, et al.
AIDS (London, England)|January 22, 2019
Metabolic syndrome and endocrine status in HIV-infected transwomenJean-David Pommier, Cedric Laouénan, Florence Michard, et al.
JAMA|July 20, 2010
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panelMelanie A Thompson, Judith A Aberg, Pedro Cahn, et al.
The Lancet. Infectious Diseases|May 14, 2013
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
The Lancet. Infectious Diseases|February 22, 2015
Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trialAntoine Chéret, Georges Nembot, Adeline Mélard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 21, 2010
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trialsRoy T Steigbigel, David A Cooper, Hedy Teppler, et al.
Pageof 7